Pfizer's outlook disappoints after Viagra loses patent protection and Lyrica faces same fate
Pharmaceutical giant Pfizer braced investors for little-to-no revenue growth in 2019 after its blockbuster erectile dysfunction drug Viagra, among others, lost patent protection and pain killer Lyrica faces similar competition from generic drugmakers this year.